All In Biotech

Drug Trial Radar · NCT06148025

Antibiotics and Vaccine Immune Responses Study

A Human Experimental Medicine Study to Assess Whether the Gut Microbiota Regulates Specific and Non-specific Immune Responses to Vaccination

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 348 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

348

Planned (sponsor's estimate)

Start

Nov 23, 2023

Primary completion

Oct 1, 2027

Study completion Oct 1, 2028

Sponsor

Lead sponsor
South Australian Health and Medical Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Royal Adelaide Hospital; Flinders University; University of Sydney; Telethon Kids Institute; Centenary Institute
First posted
Nov 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 35 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to examine immune responses to the BCG vaccine in healthy adults who have, or who have not, taken antibiotics to deplete their gut bacteria prior to vaccination. The main question it aims to answer is: does depletion of the gut microbiota lead to impaired BCG-induced protection against specific and non-specific to challenges to the immune system?

Conditions

  • Vaccine Response Impaired

Interventions

  • BCG vaccineBiological

    0.1ml injected intradermally over the distal insertion of the deltoid muscle onto the humerus

  • Yellow Fever vaccineBiological

    0.5ml injected subcutaneously

  • Vancomycin Oral CapsuleDrug

    500mg every 6 hours for 3 days

  • Neomycin Oral ProductDrug

    1000mg every 6 hours for 3 days

  • Metoclopramide (Maxolon)Drug

    10mg every 8 hours

  • Loperamide HClDrug

    2mg tablets/capsules: 2 tablets/capsules initially, followed by 1 tablet after each loose motion, to a maximum of 8 tablets/capsules per day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sub-study 1 BCG re-challengeTime frame: 2 weeks post BCG challenge
  2. Sub-study 2 Yellow Fever vaccineTime frame: 3, 5, 7 days post YFV challenge

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • South Australian Health and Medical Research Institute

    Adelaide, South Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.